TVTX

Travere Therapeutics, Inc.

Name: Travere Therapeutics, Inc. insider trading (SEC Form 4) history
Creator: U.S. Securities and Exchange Commission

SEC CIK 1438533

$52.04 +64.3% · 90 days

90-day buys

0 open-market

90-day sells

$7.82M

21 open-market

Net insider flow

−$7.82M

Net selling

Filings shown

Most recent

At a glance

Over the last 90 days, insiders at TVTX have sold a net $7.82M of stock (0 open-market buys vs 21 sells).

Largest recent trade: Baynes Roy D. sold $1.07M of TVTX, trimming their stake 37%.

Most active filer: Heerma Peter, with 28 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for TVTX, newest first

View on SEC EDGAR ↗

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · CHIEF COMMERCIAL OFFICER · Open-market sale · filed Feb 4, 2025 ΔOwn −4.0%

Heerma Peter sold $103.9K of TVTX, trimming their stake 4%.

−$103.9K

5,166 sh @ $20

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · CHIEF COMMERCIAL OFFICER · Open-market sale · filed Jan 23, 2025 ΔOwn −1.5%

Heerma Peter sold $30K of TVTX, trimming their stake 1%.

−$30K

1,584 sh @ $19

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · CHIEF COMMERCIAL OFFICER · Open-market sale · filed Sep 9, 2024 ΔOwn −2.0%

Heerma Peter sold $25.2K of TVTX, trimming their stake 2%.

−$25.2K

2,191 sh @ $12

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · CHIEF COMMERCIAL OFFICER · Open-market sale · filed Feb 2, 2024 ΔOwn −4.0%

Heerma Peter sold $35.8K of TVTX, trimming their stake 4%.

−$35.8K

4,195 sh @ $9

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · CHIEF COMMERCIAL OFFICER · Open-market sale · filed Jan 25, 2024 ΔOwn −1.9%

Heerma Peter sold $14.1K of TVTX, trimming their stake 2%.

−$14.1K

1,559 sh @ $9

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · Chief Commercial Officer · Open-market sale · filed Oct 4, 2023 ΔOwn −3.7%

Heerma Peter sold $25.5K of TVTX, trimming their stake 4%.

−$25.5K

3,091 sh @ $8

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · Chief Commercial Officer · Open-market sale · filed Feb 2, 2023 ΔOwn −2.1%

Heerma Peter sold $38.7K of TVTX, trimming their stake 2%.

−$38.7K

1,779 sh @ $22

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · Chief Commercial Officer · Open-market sale · filed Jan 26, 2023 ΔOwn −2.4%

Heerma Peter sold $34K of TVTX, trimming their stake 2%.

−$34K

1,550 sh @ $22

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · Chief Commercial Officer · Open-market sale · filed Oct 6, 2022 ΔOwn −4.5%

Heerma Peter sold $78.1K of TVTX, trimming their stake 4%.

−$78.1K

3,042 sh @ $26

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · Chief Commercial Officer · Open-market sale · filed Feb 2, 2022 ΔOwn −1.6%

Heerma Peter sold $30.8K of TVTX, trimming their stake 2%.

−$30.8K

1,125 sh @ $27

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · Chief Commercial Officer · Open-market sale · filed Jan 26, 2022 ΔOwn −3.1%

Heerma Peter sold $46.8K of TVTX, trimming their stake 3%.

−$46.8K

1,875 sh @ $25

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · Chief Commercial Officer · Open-market sale · filed Oct 5, 2021 ΔOwn −4.8%

Heerma Peter sold $75.7K of TVTX, trimming their stake 5%.

−$75.7K

3,058 sh @ $25

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · Chief Commercial Officer · Open-market sale · filed Aug 17, 2021 ΔOwn −2.2%

Heerma Peter sold $24.1K of TVTX, trimming their stake 2%.

−$24.1K

1,407 sh @ $17

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · Chief Commercial Officer · Open-market sale · filed Feb 9, 2021 ΔOwn −1.9%

Heerma Peter sold $35.5K of TVTX, trimming their stake 2%.

−$35.5K

1,125 sh @ $32

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · Chief Commercial Officer · Open-market sale · filed Feb 9, 2021 ΔOwn −1.8%

Heerma Peter sold $35.3K of TVTX, trimming their stake 2%.

−$35.3K

1,125 sh @ $31

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · Chief Commercial Officer · Open-market sale · filed Feb 3, 2021 ΔOwn −1.0%

Heerma Peter sold $16.3K of TVTX, trimming their stake 1%.

−$16.3K

563 sh @ $29

TVTX

Travere Therapeutics, Inc.

Sell Heerma Peter · Chief Commercial Officer · Open-market sale · filed Feb 3, 2021 ΔOwn −1.0%

Heerma Peter sold $17.3K of TVTX, trimming their stake 1%.

−$17.3K

563 sh @ $31

About TVTX insider activity

This page tracks every recent Form 4 filed for Travere Therapeutics, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is TVTX insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Travere Therapeutics, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.